Pharmaceutical Reviews Update — Issue 46

Program Updates

1. Consultation on Updated Procedures for Provisional Funding Algorithms Extended to May 3, 2024

On March 28, 2024, we opened a consultation to gather feedback on aspects of our draft updated procedures for provisional funding algorithms. The original deadline of April 26, 2024, has now been extended to May 3, 2024. Read our announcement to access the draft procedures and for complete details on how to participate.

2. Improving the Timeliness and Transparency of Patient and Clinician Group Input

We’re updating our Drug Reimbursement Review process to improve the timeliness and transparency of patient and clinician group input.

For patient and clinician group submissions with a call for input closing May 1, 2024, onward:  

• input will be consolidated and posted as received, as a standalone report, to ensure the original submissions are unchanged and authorship is clear. Input will be posted on our website earlier in the review process, approximately 2 weeks after the call for input closes and before the expert committee meeting.

For active submissions currently under review:  

• input will also be posted on our website as received, as a standalone report. However, it will be posted and available near the end of the review process, as per the timing outlined in our current procedures.

Rationale for These Changes

For every drug reviewed through our Reimbursement Review process, we issue a call for patient and clinician group input to gather perspectives and enhance the quality of our review.

We are implementing changes based on feedback from patient and clinician groups on how we post the input we receive. These changes were also identified through a recent Lean process review of our Drug Reimbursement Review program.

We are confident that these improvements will make it easier to find patient and clinician group input on our website and improve the transparency of the evidence reviewed by our expert committees. Input received will continue to be summarized in our clinical and pharmacoeconomic reports.

Revisions to the posting of patient and clinician group input will be reflected in an updated version of Procedures for Reimbursement Reviews in the future. Visit our website for more information on providing patient group input, clinician group input, or to find an active or completed drug review.